We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Drugs, Combo Products Will Benefit From Critical Path Institute
Drugs, Combo Products Will Benefit From Critical Path Institute
January 6, 2006
FDA’s recently established Critical Path Institute (C-Path), which aims to improve the efficiency and safety of medical product development, will benefit drug, device and combination product manufacturers, according to the institute’s director and agency officials.